格隆汇8月13日丨艾为电子(688798.SH)公布，为了提高公司募集资金使用效益，公司在确保不影响募集 资金投资项目建设、不变相改变募集资金使用用途、不影响公司正常运营及确保资金安全的情况下，同 意使用额度不超过人民币9亿元（含本数）的闲置募集资金进行现金管理，用于购买安全性高、流动性 好、满足保本要求的理财产品且该等现金管理产品不得用于质押，不用于以证券投资为目的的投资行 为，单个理财产品的投资期限不超过12个月。 ...

Core Viewpoint - The company, Aiwei Electronics (688798.SH), has announced a plan to utilize up to RMB 900 million of idle raised funds for cash management, ensuring that this does not affect the construction of investment projects or the normal operation of the company [1] Group 1 - The company aims to improve the efficiency of fund usage by investing in high-security, liquid financial products that meet capital preservation requirements [1] - The cash management products will not be used for pledging or for securities investment purposes [1] - The investment period for individual financial products will not exceed 12 months [1]

Core Viewpoint - Wuhan Keqian Biological Co., Ltd. plans to sign a cooperative research and development agreement with Huazhong Agricultural University, involving four vaccine projects, with a total payment of 4.9 million RMB [2][4][67]. Group 1: Overview of Related Transactions - The company has obtained cooperation for the development of four projects: "Canine Distemper, Canine Parainfluenza, Canine Adenovirus and Canine Parvovirus Quadrivalent Live Vaccine - Inactivated Canine Coronavirus Vaccine," "Porcine Gata Virus Inactivated Vaccine," "Porcine Proliferative Enteropathy Blocking ELISA Antibody Test Kit," and "NADC30-like Porcine Reproductive and Respiratory Syndrome Live Vaccine (GX2024 Strain)" [2][4][67]. - The total payment to Huazhong Agricultural University for these projects is 4.9 million RMB, with specific allocations of 1.5 million RMB, 2 million RMB, 400,000 RMB, and 1 million RMB for each project respectively [4][67]. - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [2][4][67]. Group 2: Necessity and Impact of Related Transactions - The cooperative research aims to enhance the company's product portfolio and market competitiveness, although the success of the projects and their market introduction remain uncertain [67]. - The pricing and process of the transaction comply with legal regulations and do not harm the interests of the company or minority shareholders [67]. Group 3: Approval Procedures for Related Transactions - The board of directors and the supervisory board have approved the agreement, with related directors abstaining from voting [68][69]. - Independent directors have expressed that the agreement will enhance the company's core competitiveness in the biological products sector and that the transaction process is legal and fair [71][72]. Group 4: Research and Development Agreement Details - The agreement includes provisions for the rights and obligations of both parties, including the management of research funds and the ownership of intellectual property generated from the projects [8][37][52]. - The agreement is valid for 10 years, with provisions for extension and termination under certain conditions [20][36][66].

Core Viewpoint - The company plans to utilize idle raised funds for cash management, not exceeding RMB 260 million, to enhance fund efficiency while ensuring the normal operation of fundraising projects and maintaining fund safety [1][2][8] Summary by Sections Investment Purpose - The company aims to improve fund efficiency and increase shareholder returns by managing temporarily idle raised funds, ensuring it does not affect the progress of fundraising projects [5][7] Fund Source and Limit - The company will use up to RMB 260 million of idle raised funds for cash management, which can be rolled over within the specified limit [2][5] Investment Duration - The investment period is valid for 12 months from the date of the board's approval [5][6] Investment Method - The company will invest in high-security, liquid products such as structured deposits, time deposits, and large certificates of deposit, ensuring compliance with relevant regulations [5][6] Impact on Daily Operations - The cash management of idle funds will not affect the normal operation of fundraising projects and is expected to enhance overall performance and shareholder returns [7][8] Approval Process - The proposal for cash management has been approved by the board and supervisory board, complying with legal and regulatory requirements [8]

Summary of Key Points Core Viewpoint - The company intends to utilize idle raised funds for cash management to enhance fund efficiency and shareholder returns while ensuring that it does not affect the ongoing investment projects or the normal operations of the company [1][6]. Group 1: Fundraising and Usage - The company raised a total of RMB 1,227.45 million from its initial public offering (IPO) by issuing 105 million shares at a price of RMB 11.69 per share, with a net amount of RMB 1,141.73 million after deducting issuance costs of RMB 85.72 million [1][2]. - The total investment amount for the projects funded by the IPO is RMB 1,799.19 million, with RMB 1,747.03 million allocated from the raised funds [2]. - Due to a lower-than-expected net amount from the IPO, the company adjusted its investment projects, excluding certain projects and reallocating funds to ensure efficient use [2][3]. Group 2: Cash Management Plan - The company plans to use up to RMB 260 million of idle raised funds for cash management, ensuring that it does not impact the investment projects or the company's operations [3][5]. - The investment period for the cash management is valid for 12 months from the board's approval date, with a focus on low-risk, high-liquidity investment products [3][4]. - The income generated from cash management will be used to supplement any shortfall in the investment amounts for the projects and will be returned to the raised funds account upon maturity [4][6]. Group 3: Impact on Operations - The cash management of idle funds is expected to improve the efficiency of fund usage without affecting the normal progress of investment projects or the company's core business [4][6]. - By managing idle funds effectively, the company aims to achieve additional investment returns, thereby enhancing overall performance and providing greater returns to shareholders [4][6]. Group 4: Compliance and Approval - The cash management plan has been approved by the company's board and supervisory board, complying with relevant laws and regulations [5][6]. - The company will adhere to strict risk control measures and disclose information as required by regulatory authorities [4][6].

证券日报网讯 8月12日晚间，科前生物发布公告称，公司2025年8月12日召开第四届董事会第十三次会 议、第四届监事会第十二次会议审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司 使用额度不超过人民币26，000万元（含本数）的闲置募集资金在确保不影响募集资金投资项目进度、 不影响公司正常生产经营及确保资金安全的情况下进行现金管理，在上述额度范围内，资金可以滚动使 用，使用期限自公司董事会审议通过之日起12个月内有效。 （文章来源：证券日报） ...

格隆汇8月12日丨科前生物(688526.SH)公布，在确保不影响募集资金投资计划正常进行、不影响公司正 常生产经营及确保资金安全的前提下,使用不超过人民币26,000万元（含本数）的闲置募集资金进行现金 管理。该等闲置募集资金在上述额度内可在投资期限内滚动使用。 ...

格隆汇8月12日丨科前生物(688526.SH)公布，在确保不影响募集资金投资计划正常进行、不影响公司正 常生产经营及确保资金安全的前提下,使用不超过人民币26,000万元（含本数）的闲置募集资金进行现金 管理。该等闲置募集资金在上述额度内可在投资期限内滚动使用。 ...

| 受托方名称 | 产品类型 | 产品名称 | 起始日 | 到期日 | 本金 | 金额 | | --- | --- | --- | --- | --- | --- | --- | | | | | （万元） | （万元） | | | | 交通银行股份有 | 结构性存 | 交通银行蕴通财富定 | 2025年5 | 2025年8 | | | | 限公司宿迁分行 | 款 | 期型结构性存款98天 | 月6日 | 月12日 | | | | | （挂钩汇率看涨） | | | | | | 二、截至本公告日，公司最近十二个月使用闲置募集资金进行现金管理的 情况 单位：万元 尚未收回本 序号 现金管理产品类型 实际投入金额 实际收回本金 实际收益 金 证券代码：603065 证券简称：宿迁联盛 公告编号：2025-047 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宿迁联盛科技股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日分别 召开了第三届董事会第三次会议和第三届监事会第三次会议，审议通过《关于使 用部分闲置募集资金进行 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 青岛德固特节能装备股份有限公司（以下简称"公司"）于2025年4月18日召开第五届董事会第五次会 议、第五届监事会第五次会议，审议通过了《关于公司使用闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设、不影响公司正常运营及确保资金安全的情况下，使用闲置募 集资金额度不超过人民币3,000万元（含本数）进行现金管理，使用期限自董事会审议通过之日起12个 月内有效。在上述额度及期限内，资金可循环滚动使用。具体内容详见公司2025年4月22日公布在巨潮 资讯网（www.cninfo.com.cn）上的《关于使用闲置募集资金进行现金管理的公告》（公告编号：2025- 020）。 1、投资风险 （1）公司的投资产品均经过严格评估，但金融市场受宏观经济影响，不排除该项投资受到市场波动的 影响。 （2）公司将根据经济形势以及金融市场的变化适时适量介入，不排除受到市场波动的影响，短期投资 的收益不可预测。 （3）相关工作人员的操作和监控风险。 2、风险控 ...